Erratum: Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer (Oncotarget (2016) 7 (38500-38512) DOI: 10.18632/oncotarget.9522);Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer

Oncotarget

Volumn 7, Issue 25, 2016, Pages 38500-38512

  Lee, Kyung Min ^a,b   Lee, Minju ^b   Lee, Jiwoo ^a,b   Kim, Sung Wuk ^c   Moon, Hyeong Gon ^b   Noh, Dong Young ^b   Han, Wonshik ^b  

^a Seoul National University Biomedical Research Institute   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Cellumed Co   (South Korea)

Author keywords

Anti cancer drug; Breast cancer; G2 M arrest; Metformin analog; Stem cell population

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; METFORMIN BUTYRATE; UNCLASSIFIED DRUG; BUTYRIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CELL CYCLE PROGRESSION; CELL GROWTH; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; S PHASE CELL CYCLE CHECKPOINT; TUMOR GROWTH INHIBITION RATE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; BUTYRATES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; METFORMIN; MICE; NEOPLASTIC STEM CELLS;

EID: 84978062327     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.27986     Document Type: Erratum

References (48)

1. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ: British Medical Journal. 2005; 330:1304-1305.
2. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM. New Users of Metformin Are at Low Risk of Incident Cancer A cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32:1620-1625.
3. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association Between Metformin Therapy and Mortality After Breast Cancer A population-based study. Diabetes Care. 2013; 36:3018-3026.
4. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu LM, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. Journal of Clinical Oncology. 2009; 27:3297-3302.
5. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission. Cancer Research. 2009; 69:7507-7511.
6. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009; 8:2031-2040.
7. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27:3576-3586.
8. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin Disrupts Crosstalk between G Protein-Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth. Cancer Research. 2009; 69:6539-6545.
9. Dowling RJO, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. Bmc Medicine. 2011; 9.
10. Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y, Zhao WL. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death & Disease. 2012; 3.
11. Guppy A, Jamal-Hanjani M, Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncology. 2011; 7:727-736.
12. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in Breast Cancer: Time for Action. Journal of Clinical Oncology. 2009; 27:3271-3273.
13. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell cycle. 2010; 9:1057-1064.
14. Zhuang Y, Miskimins WK. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. Journal of molecular signaling. 2008; 3:18.
15. Alimova IN, Liu BL, Fan ZY, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009; 8:909-915.
16. Zhuang Y, Miskimins WK. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. Journal of molecular signaling. 2008; 3:18.
17. Shapiro GI, Harper JW. Anticancer drug targets: cell cycle and checkpoint control. Journal of Clinical Investigation. 1999; 104:1645.
18. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell proliferation. 2003; 36:131-149.
19. Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Current pharmaceutical design. 2000; 6:379-392.
20. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annual review of medicine. 2007; 58:267-284.
21. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:3983-3988.
22. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature reviews Cancer. 2009; 9:265-273.
23. Wicha MS. Targeting breast cancer stem cells. Breast. 2009; 18:S56-58.
24. Liu S, Wicha MS. Targeting breast cancer stem cells. Journal of clinical oncology. 2010; 28:4006-4012.
25. Federici G, Espina V, Liotta L, Edmiston KH. Breast cancer stem cells: a new target for therapy. Oncology (Williston Park). 2011; 25:25-28, 30.
26. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Research and Treatment. 2011; 126:355-364.
27. Vazquez-Martin A, Oliveras-Ferraros C, Cuff S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle. 2010; 9:3807-3814.
28. Song CW, Lee H, Dings RPM, Williams B, Powers J, Dos Santos T, Choi BH, Park HJ. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Scientific Reports. 2012; 2.
29. Lonardo E, Cioffi M, Sancho P, Sanchez-Ripoll Y, Trabulo SM, Dorado J, Balic A, Hidalgo M, Heeschen C. Metformin Targets the Metabolic Achilles Heel of Human Pancreatic Cancer Stem Cells. Plos One. 2013; 8.
30. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer Doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 2010; 9:1057-1064.
31. Dowling RJO, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. Journal of Molecular Endocrinology. 2012; 48:R31-R43.
32. Han G, Gong HJ, Wang YD, Guo SW, Liu K. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biology & Therapy. 2015; 16:77-87.
33. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences. 2003; 100:3983-3988.
34. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Medical Oncology. 2012; 29:1314-1327.
35. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: A Therapeutic Opportunity in Breast Cancer. Clinical Cancer Research. 2010; 16:1695-1700.
36. Ben Sahra I, Tanti JF, Bost F. The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy. 2010; 6:670-671.
37. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin induces apoptosis of pancreatic cancer cells. World Journal of Gastroenterology. 2008; 14:7192-7198.
38. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, Bost F. Targeting Cancer Cell Metabolism: The Combination of Metformin and 2-Deoxyglucose Induces p53-Dependent Apoptosis in Prostate Cancer Cells. Cancer Research. 2010; 70:2465-2475.
39. Nakanishi M, Ando H, Watanabe N, Kitamura K, Ito K, Okayama H, Miyamoto T, Agui T, Sasaki M. Identification and characterization of human Wee1B, a new member of the Wee1 family of Cdk-inhibitory kinases. Genes to Cells. 2000; 5:839-847.
40. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Annals of Oncology. 2009:mdp492.
41. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109:25-32.
42. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical Cancer Research. 2008; 14:1368-1376.
43. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. Journal of Clinical Oncology. 2006; 24:5652-5657.
44. Liu BL, Fan ZY, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009; 8:2031-2040.
45. Deng X-S, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012; 11:367-376.
46. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences. 2009; 106:13820-13825.
47. Honeth G, Bendahl P-O, Ringnér M, Saal LH, Gruvberger-Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt C. The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008; 10:R53.
48. Lee KM, Han W, Kim JB, Shin I, Ko E, Park IA, Lee DS, Oh K, Noh DY. The CD49d(+/high) subpopulation from isolated human breast sarcoma spheres possesses tumorinitiating ability. International Journal of Oncology. 2012; 40:665-672.